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Abstract 
Background: Cancer incidence and mortality have been increasing in China, making cancer the leading cause of 
death since 2010 and a major public health concern in the country. Cancer stem cells have been studied in relation to 
the treatment of different malignancies, including gastric cancer. Anticancer bioactive peptide-3 (ACBP-3) can induce 
the apoptosis of gastric cancer stem cells (GCSCs) and reduce their tumorigenicity. In the present study, for the first 
time, we used a miRNA microarray and bioinformatics analysis to identify differentially expressed miRNAs in ACBP-3-
treated GCSCs and GCSC-derived tumors in a xenograft model and functionally verified the identified miRNAs. miR-
338-5p was selected based on its significant upregulation by ACBP-3 both in cultured GCSCs and in tumor tissues.
Results: miR-338-5p was downregulated in GCSCs compared with normal gastric epithelial cells, and the ectopic 
restoration of miR-338-5p expression in GCSCs inhibited cell proliferation and induced apoptosis, which correlated 
with the upregulation of the pro-apoptotic Bcl-2 proteins BAK and BIM. We also found that ACBP-3-treated GCSCs 
could respond to lower effective doses of cisplatin (DDP) or 5-fluorouracil (5-FU), possibly because ACBP-3 induced 
the expression of miR-338-5p and the BAK and BIM proteins and promoted GCSC apoptosis.
Conclusions: Our data indicate that miR-338-5p is part of an important pathway for the inhibition of human gastric 
cancer stem cell proliferation by ACBP-3 combined with chemotherapeutics. ACBP-3 could suppress GCSC prolifera-
tion and lower the required effective dose of cisplatin or 5-fluorouracil. Therefore, this study provides not only further 
evidence for the remarkable anti-tumor effect of ACBP-3 but also a possible new approach for the development of 
GCSC-targeting therapies.
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Background
Gastric cancer (GC) is one of the major threats to human 
health worldwide. More than 60  % of newly diagnosed 
cases have been detected in Eastern Asia [1]. Cancer 
incidence and mortality have been increasing in China, 
making cancer the leading cause of death since 2010 and 
a major public health concern in the country. It is pre-
dicted that there will be approximately 4,292,000 newly 
diagnosed invasive cancer cases in 2015 in China, cor-
responding to almost 12,000 new cancer diagnoses on 
average each day (The total number of cases projected 
for 2015 are based on the average incidence rates for 
the most recent 3 years (2009–2011) using data from 72 
population-based cancer registries) [2]. It has been sug-
gested that cancer stem cells (CSCs), found in many types 
of tumors, and may be responsible for cancer relapse and 
metastasis. Although the CSC population in tumors is 
very small, CSCs are thought to underlie the malignant 
phenotype of tumors, including cancer initiation, angio-
genesis, and invasiveness, metastasis, and drug resistance 
[3]. Although new chemotherapeutic, radio therapeu-
tic and surgical methods have been developed to treat 
GC, the 5-year survival rate has not improved. One of 
the main reasons is the existence of gastric cancer stem 
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cells (GCSCs), which can resist chemo- and radiother-
apy, escape from apoptosis, and proliferate infinitely [4], 
whereas differentiated GC cells are eliminated. Thus, 
therapeutic approaches targeting GCSCs in GC have 
been a focus of recent research.
Natural antitumor agents have attracted considerable 
attention because of their low toxicity and powerful anti-
tumor activity. Anticancer bioactive peptide-3 (ACBP-3), 
a polypeptide isolated from goat liver in our laboratory, 
has been shown to inhibit proliferation, induce apopto-
sis, and reduce the tumorigenicity of human GCSCs both 
in vitro and in vivo. In addition, ACBP-3 could lower the 
required effective dose of DDP and improve the condi-
tion of mice bearing GCSC-originating tumors [5]. How-
ever, the mechanisms underlying the ACBP-3-mediated 
suppression of GCSCs remains unknown.
MicroRNAs (miRNAs) are small non-coding RNAs of 
approximately 22 nucleotides that function by targeting 
mRNAs and regulating gene expression. miRNAs are 
involved in multiple physiological and pathological pro-
cesses [6], including cancer, in which they regulate cell 
proliferation, differentiation, infiltration, and apoptosis 
[7, 8]. Thus, miRNA microarrays are widely used as a 
powerful tool for analyzing the responses of cancer cells 
to treatments.
In the present study, we investigated the inhibi-
tory activity of ACBP-3 against GCSCs using a miRNA 
microarray followed by bioinformatics analysis to screen 
for miRNAs that are differentially regulated in ACBP-
3-treated GCSCs (Fig.  1a). The identified miRNA miR-
338-5p was functionally verified in GCSCs exposed 
to chemotherapeutic drugs or drugs combined with 
ACBP-3 and were shown to inhibit GCSC proliferation 
via the upregulation of apoptosis. Thus, in this study, we 
present a mechanism of ACBP-3 activity against GCSCs 
that explains the potentiating effect of ACBP-3 on cancer 
cell inhibition by chemotherapeutic drugs.
Results
Selection of miRNA species differentially expressed 
in ACBP‑3‑treated GCSCs
The comparison of miRNA expression profiles identi-
fied 20 and nine miRNAs in ACBP-3-treated GCSCs and 
controls, respectively that were significantly differen-
tially expressed (Fig.  1b, c). The differentially expressed 
miRNAs detected in two chips did not overlap, so, after 
multiple rescreening processes, nine miRNAs signifi-
cantly upregulated by ACBP-3 (P  <  0.05) were selected 
for further analysis: hsa-miR-1469, hsa-miR-762, hsa-
miR-338-5p, hsa-miR-3173-3p, hsa-miR-4467, hsa-miR-
3940-5p, hsa-miR-3195, hsa-miR-3621, and hsa-miR-663a 
(Table 1). To determine the putative biological functions 
of the selected miRNAs, TargetScan and Mirdb were used 
to identify 639 miRNA target genes, which were subjected 
to multiple analyses, including GO analysis (Additional 
file 1: Figure S1), pathway analysis (Additional file 1: Fig-
ure S2), miRNA-gene-network analysis (Additional file 1: 
Figure S3), and mRNA-GO-network analysis (Additional 
file  1: Figure S4) to select functionally relevant genes 
involved in carcinogenesis. In Additional file  1: Figure 
S3, the miRNA-338-5p, the miRNA—338-3 p and the 
miRNA-762-5 miRNAs play a key role in the network, 
especially the miRNA-338-5p regulated most genes in the 
network, to 131, including the BCL-2 families and KRAS 
families of related tumor genes. In the microarray results, 
we observed that the miRNA-3173-3p regulated BAK and 
the miRNA-338-5p regulated BIM (BCL2L11).
miR‑338‑5p expression in GCSCs and normal gastric 
epithelial cells
As miR-338-5p demonstrated the highest upregula-
tion by ACBP-3, it was selected for validation by qRT-
PCR. We compared the relative miR-338-5p expression 
in GCSCs and normal human gastric epithelial GES-1 
cells and found that the miR-338-5p levels were 1.96 and 
1.71 times higher in GES-1 cells than in MKN45- and 
MKN74G-derived GCSCs, respectively (Fig. 1d).
miR‑338‑5p‑mediated inhibition of GCSC proliferation
To clarify the functional role of miR-338-5p, its mimic 
and inhibitor were used to transfect GCSCs. Transfec-
tion with miR-338-5p resulted in 19.71-and 28.29-fold 
upregulation of the miR-338-5p levels in MKN45- and 
MKN74-derived GCSCs, respectively (P < 0.01), whereas 
the miR-338-5p inhibitor decreased miR-338-5p levels 
by 58.4 and 39.6 %, respectively, of the control (P < 0.01) 
(Additional file  1: Figure S5 A–D). There was no differ-
ence between the controls in each group (P > 0.05). The 
MTT assay indicated that miR-338-5p overexpression 
inhibited the proliferation of MKN45-derived cells by 
16.95 % ± 1.19 (P < 0.05), 32.48 % ± 2.26 (P < 0.01), and 
43.89 % ± 5.72 (P < 0.01) at 24, 48, and 72 h post-trans-
fection, respectively, whereas the miR-338-5p inhibitor 
had no effect (P  >  0.05) (Fig.  2a). Similar changes were 
observed in miR-338-5p-transfected MKN74 GCSCs, in 
which cell proliferation was inhibited to 48.63 % ± 6.03 
and 48.21 % ± 4.91 of that in the control cells at 48 and 
72 h, respectively (P < 0.05; Fig. 2b).
Viable cell counting confirmed the above results. At 
48  h post-transfection, the cell numbers decreased to 
25.33 % ± 2.14 (P < 0.01) and 34.51 % ± 4.02 (P < 0.05), and 
at 72 h, the cell numbers were 36.05 % ± 2.57 (P < 0.01) 
and 35.31 % ± 4.11 (P < 0.05) for miR-338-5p-transfected 
MKN45 and MKN74 GCSCs, respectively, compared with 
the controls (Fig. 2c, d). However, the miR-338-5p inhibi-
tor did not significantly affect cell viability (P > 0.05).
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miR‑338‑5p induction of GCSC apoptosis
To evaluate the effects of miR-338-5p on the apoptosis of 
GCSCs, transfected GCSCs were analyzed by Annexin 
V-PI staining. There was a significant difference in apop-
tosis between the control and miR-338-5p-transfected 
MKN45-derived GCSCs and MKN74-derived GCSCs 
(Fig.  3a, b). No difference in apoptosis was observed 
between the control and miR-338-5p inhibitor-transfected 
GCSCs (P > 0.05). Figure 3a shows that the apoptosis rate 
of miR-338-5p-transfected MKN45-derived GCSCs was 
increased compared with control cells (13.23  ±  0.09 vs 
3 ± 0.27 %, respectively; P < 0.05). Similarly, Fig. 3b shows 
that apoptosis was increased in miR-338-5p-transfected 
MKN74-derived GCSCs (23.87 ± 0.16 % vs 17.6 ± 0.45 in 
the control). As in the previous experiments, transfection 
with the miR-338-5p inhibitor had no effect (P > 0.05).
miR‑338‑5p deregulation of the cell cycle
The effects of miR-338-5p on the cell cycle were 
assessed in GCSCs 48  h post-transfection by flow 
Fig. 1 A mechanism of human gastric cancer stem cell inhibition by anticancer bioactive peptide-3 (a). Effects of ACBP-3 on miRNA expression in 
human GCSCs. Twenty and nine significantly differentially expressed miRNAs were identified in cultured GCSCs (b) (P < 0.05). c Down regulation of 
the relative miR-338-5p expression in GCSCs compared with normal human gastric epithelial cells, (*P < 0.05, compared with gastric epithelial GES-1 
cells)
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cytometry after Annexin V-PI staining. The results 
indicate that miR-338-5p decreased the proportion 
of GCSCs in the G0/G1 phase and increased the pro-
portion in the S and G2/M phases (P  <  0.01), whereas 
the miR-338-5p inhibitor did not cause significant cell 
cycle changes in GCSCs (Fig. 3c–f ). Another result was 
reported in a recent study, in which the transfection 
of miR-199a-5p inhibitors increased the expression of 
CTGF and promoted the viability of the cells by increas-
ing the fraction of cells in the G2/M and S phases [9]. 
Another study reported the Cadmium (Cd)-induced 
reduction of the number of G0/G1 phase cells and an 
increase in the number of cells in S phase and G2/M 
phase, which showed that Cd-induced ROS forma-
tion promoted HMGA2 upregulation, causing changes 
in the cell cycle [10]. Therefore, the over-expression of 
miR-338-5p decreased the number of GCSCs in G0/
G1 phase and increased the number of GCSCs in S and 
G2/M phase, causing changes in the cell cycle changes 
and making the cells more likely to be inhibited by 
chemotherapy drugs. Thus, miR-338-5p, as an anti-can-
cer gene, can inhibit GCSC proliferation.
Table 1 Nine miRNAs selected after rescreening










Fig. 2 Effect of miR-338-5p expression on GCSC proliferation. Cell proliferation was assessed by the MTT assay in MKN45-derived (a, c) and MKN74-
derived GCSCs (b, d) 24 h, 48 h, and 72 h after transfection with miR-338-5p mimic or inhibitor. The effect of miR-338-5p expression on GCSC 
viability was determined by an MTT assay. Viable cells were counted in MKN45 (c) and MKN74 GCSCs (d) 24 h, 48 h, and 72 h after transfection with 
miR-338-5p mimic or inhibitor (Filled circle represents the control, open circle represents the vehicle control, filled inverted traingle represents the 
mimic, open triangle represents the inhibitor). *(P < 0.05) and **(P < 0.01) represent comparisons of two symbols in the same row at a set time
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In a recent study, the BH3-only protein  BIM,  a key 
post-transcriptional repressor of BIM expression, and 
the activation of BAX/BAK were shown to be depend-
ent on mitochondrial (intrinsic) apoptosis [11]. Micro-
array results predicted that mir-338-5p is regulated by a 
target gene network consisting of 2 closely related genes, 
namely BAK and BIM (BCL2L11), directly or indirectly 
[12]. To verify the induction of apoptosis by miR-338-5p 
in GCSCs, the expression of the pro-apoptotic proteins 
BIM and BAK was measured by western blotting (Fig. 4a, 
b). β-actin was used as a reference for the relative level of 
BIM (Additional file 1: Figure S6 A, C) and BAK (Addi-
tional file 1: Figure S6 B, D) in transfected MKN45 cells 
(Additional file  1: Figure S6 A, B) and MKN74 cells 
(Additional file 1: Figure S6 C, D). The data indicated that 
the BIM and BAK levels were increased in both MKN45- 
and MKN74-derived GCSCs after transfection with 
miR-338-5p compared with control GCSCs (P  <  0.05; 
Fig. 4a, b), confirming the results of flow cytometry.
Expression of BIM and BAK in GCSCs treated with different 
drug combinations
Given that miR-338-5p overexpression accelerated GCSC 
apoptosis and that ACBP-3 (alone or in combination with 
chemotherapeutic drugs) potently upregulated miR-338-5p 
levels, we investigated the expression of the pro-apoptotic 
proteins BIM and BAK in GCSCs treated with ACBP-
3, DDP and 5-FU, alone or in combination. The protein 
expression of BIM and BAK in GCSCs treated with 5-FU, 
DDP groups, 5-Fu/ACBP-3, DDP/ACBP-3, ACBP-3 or a 
control treatment for 48  h is shown in Fig.  4c, d. β-actin 
was used as a reference for the relative level of BIM (Addi-
tional file 1: Figure S6 E, G) and BAK (Additional file 1: Fig-
ure S6 F, H) in MKN45 cells (Additional file 1: Figure S6 E, 
Fig. 3 PI/Annexin-V double staining evaluating the effect of miR-338-5p expression on apoptosis and the cell cycle in GCSCs. Untreated control 
cells and cells treated with a mimic, inhibitor or vehicle control were evaluated for MKN45 cells (a, c) and MKN74 cells (b, d) by flow cytometry. The 
cell cycle phase distribution of MKN45-derived GCSCs (e) and MKN74-derived GCSCs (f) is described 48 h post-transfection
Page 6 of 12Xing et al. Cell Biosci  (2016) 6:53 
F) and MKN74 cells (Additional file 1: Figure S6 G, H). The 
results showed that in GCSCs, the expression of BIM and 
BAK positively correlated with that of miR-338-5p. Thus, 
the BIM and BAK levels were the highest after treatment 
with ACBP-3, followed by its combination with chemo-
therapeutic drugs and 5-FU or DDP alone. These results 
suggest that miR-338-5p could play an important role in 
the anti-GCSC effects of ACBP-3 by inducing GCSC apop-
tosis via the upregulation of BIM and BAK expression.
Determination of experimental doses 
for chemotherapeutic drugs
ACBP-3 could lower the required effective dose of 
DDP, enhance its therapeutic efficiency, and improve 
the survival of tumor-bearing mice [5]. Here, we 
used a combination of ACBP-3 with DDP and 5-FU 
to analyze the effects on GCSCs in  vitro. To deter-
mine the IC50 for DDP and 5-FU in GCSCs, the 
cells were treated with increasing doses of DDP and 
5-FU for 24, 48, or 72  h, and the IR was calculated. 
Both DDP and 5-FU inhibited GCSCs in a dose-and 
time-dependent manner. Thus, for MKN45-derived 
GCSCs, the IR increased from 7.16 ±  0.06 % at 1 μg/
ml DDP to 48.99  ±  0.04  % at 21  μg/ml DDP after 
24  h of treatment, and from 36.91  ±  0.06  % at 24  h 
to 49.80 ± 0.03 % at 48 h and 65.25 ± 0.04 % at 72 h 
for 3.5  μg/ml DDP (P  <  0.01; Fig.  5). Similar dynam-
ics were observed for 5  μg/ml of 5-FU (Fig.  5). Based 
on these data, the IC50 was calculated (Table 2). How-
ever, a linear increase in the IR was observed only 
within a certain drug concentration range and disap-
peared at higher doses (Fig. 6a, b). Thus, 199.10 μg/ml 
Fig. 4 Correlation between miR-338-5p expression and the relative level of BIM and BAK. BIM and BAK expression was analyzed by western blotting 
in GCSCs transfected with miR-338-5p mimic and inhibitor. Representative blots are shown for miR-338-5p overexpression experiments in trans-
fected MKN45 (a) and MKN74 GCSCs (b). β-actin was used as a reference. The protein expression of BIM and BAK is shown for GCSCs treated with 
5-FU, DDP groups, 5-Fu/ACBP-3, DDP/ACBP-3, ACBP-3 or a control for 48 h. Transfected MKN45 cells (c) and MKN74 cells (d) are shown, and β-actin 
was used as a reference
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5-FU caused 50 % inhibition (IC50) of MKN74-derived 
GCSCs, whereas a significantly lower dose (40 μg/ml) 
caused 42.16 % inhibition. Therefore, we chose 40 μg/
ml 5-FU for MKN74-derived GCSCs; in other cases, 
the IC50 was used. Both MKN45- and MKN74-derived 
GCSCs treated with different drug doses for 48  h 
remained stable; therefore, we chose 48 h as the treat-
ment period in further experiments.
ACBP‑3 potentiation of DDP and 5‑FU cytotoxicity 
for GCSCs
GCSCs were treated with 5-FU and DDP at a concentra-
tion of 0.5 IC50 alone or in combination with 22  μg/ml 
ACBP-3 [5] and analyzed for the IR. The results showed 
that in MKN45-derived GCSCs, both drugs combined 
with ACBP-3 caused significantly stronger inhibition of 
cell proliferation than when the drugs were used alone 
(P < 0.01; Fig. 6a, b), whereas in MKN74-derived GCSCs, 
DDP in combination with ACBP-3 inhibited cell prolifer-
ation more effectively than when the drug was used alone 
(P < 0.01; Fig. 6a, b). However, the combination of 5-FU 
with ACBP-3 had the same effect on MKN74-derived 
GCSCs as 5-FU alone, although it was higher than that of 
ACBP-3 alone (P < 0.01).
Relative miR‑338‑5p expression in GCSCs treated 
with different drug combinations
The above results confirmed that ACBP-3 potentiated the 
anti-GCSC activity of DDP and 5-FU, which is consistent 
with the findings in vivo [5]. To address the mechanism 
Fig. 5 Inhibition of cell proliferation. Inhibition of MKN45-derived (a, b) and MKN74-derived (c, d) GCSC proliferation by DDP (a, c) and 5-FU (b, d). 
Cell proliferation was determined by an MTT assay after 24, 48, and 72 h of exposure to different doses of the chemotherapeutic agents
Table 2 IC50 values of chemotherapeutic drugs for MKN45-
derived GCSCs (μg/mg) and MKN74-derived GCSCs (μg/ml)
24 h 48 h 72 h
MKN45
DDP 12.72 3.85 1.75
5-FU 111.43 11.87 8.28
MKN74
DDP 30 10.62 3.16
5-FU 313.87 199.10 2.57
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underlying the observed synergy, we investigated miR-
338-5p expression in drug-treated GCSCs. The results 
indicated that in all treated MKN45- and MKN74-
derived GCSCs, miR-338-5p expression was higher 
compared with the control (P < 0.01 and P < 0.05, respec-
tively). ACBP-3 alone increased the miR-338-5p levels 
more than 10 times compared with the control (P < 0.01) 
and significantly elevated the miR-338-5p levels in com-
bination with 5-FU or DDP compared with the drugs 
alone (P  <  0.01; Fig.  6c, d). These results suggest that 
miR-338-5p upregulation by ACBP-3 may be the mecha-
nism responsible for the ACBP-3-mediated potentiation 
of the cytotoxic effects of drugs against GCSCs.
Discussion
CSCs can self-renew for a long time and generate dif-
ferentiated cancer cell progeny [13] because of impaired 
cell cycle checkpoint control and apoptosis regulation as 
well as decreased DNA sensitivity to chemotherapy and 
radiotherapy effects due to the upregulation of multidrug 
resistance proteins [3]. CSCs can divide asymmetrically 
to generate differentiated cancer cells or symmetrically 
to maintain a stable population of their own, which 
accounts for their resistance to cytotoxic drugs [14, 15] 
and radiation [16]. A sudden decrease in tumor size due 
to radical treatments may change the microenvironment 
and activate CSCs [17], leading to tumor relapse and 
Fig. 6 Inhibition of GCSC proliferation by a combination of chemotherapeutic drugs and ACBP-3. MKN45-derived GCSCs (a); MKN74-derived GCSCs 
(b). Asterisks representing DDP/ACBP-3 and ACBP-3 vs DDP, P < 0.01; hash symbol representing ACBP-3 vs 5-FU, P < 0.01; open circle and filled triangle 
representing ACBP-3 vs DDP/ACBP-3 and 5-FU/ACBP-3, P < 0.01, respectively. Relative miR-338-5p expression in GCSCs treated with ACBP-3 and 
chemotherapeutic drugs. GCSCs derived from MKN45 (c) and MKN74 (d) were treated with ACBP-3 alone or in combination with 5-FU or DDP for 
48 h and analyzed for miR-338-5p expression. *P < 0.05, **P < 0.01, 5-FU/ACBP-3 vs 5-FU; filled traingle representing DDP/ACBP-3 vs DDP, P < 0.01; 
filled circle representing ACBP-3 vs other treatments, P < 0.01
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metastasis [18]. Therefore, effective CSC-targeting thera-
pies would significantly improve cancer prognosis.
Using MKN45 and MKN74 cells, which have the high-
est GCSC population among human GC cell lines [19], 
we have found that ACBP-3 exerted GCSC-suppressive 
effects in vitro and in vivo. Here, we observed that miR-
338-5p was highly upregulated by ACBP-3 in cultured 
GCSCs and GCSC-derived tumors. miR-338 is consid-
ered a central nervous system-specific miRNA encoded 
in the intron of the AATK (Apoptosis-associated Tyros-
ine Kinase) gene [20], which is upregulated during the 
apoptosis of myeloid precursor cells [21], and cerebellar 
granule neurons cultured in low-potassium conditions 
[22]. In miRNA biogenesis, one strand is loaded in the 
RNA-induced silencing complex, whereas the other is 
destroyed [23]; but for miR-338, both miR-338-3p and 
miR-338-5p work as transcriptional repressors [24–26]. 
Previous studies have indicated that miR-338 and miR-
338-3p are downregulated in gastric cancer [27, 28], 
esophageal squamous carcinoma [29, 30], hepatocellular 
carcinoma [31, 32], and neuroblastoma [33] and upregu-
lated in oral cancer [34], pancreatic cancer [35], and oste-
osarcoma [36], suggesting cancer type-specific effects. 
However, the activity of miR-338-5p has been rarely 
reported, and the functional relationship between miR-
338-3p and miR-338-5p remains unclear.
The present study revealed that miR-338-5p was 
downregulated in GCSCs compared with normal gas-
tric epithelial cells, suggesting that miR-338-5p may 
function as an inhibitor of GC development. Given that 
ACBP-3 induced miR-338-5p in GCSCs and GCSC-
initiated tumors, the inhibitory effect of ACBP-3 on 
GCSCs could be due to the upregulation of miR-338-5p 
expression. ACBP-3 also inhibited proliferation and pro-
moted apoptosis in GCSCs, which directly correlated 
with miR-338-5p upregulation, as demonstrated in miR-
338-5p-transfected GCSCs [36]. However, a miR-338-5p 
inhibitor did not show any effects, probably because 
the starting level of miR-338-5p expression was already 
downregulated to the baseline and could not be function-
ally inhibited any further.
Interestingly, in contrast to cell proliferation and viabil-
ity inhibition, a miR-338-5p mimic induced the transi-
tion of GCSCs to the S or G2/M phase of the cell cycle, 
i.e., accelerated GCSC division. GCSCs have consider-
able resistance to chemotherapeutic agents due to their 
relative quiescence and secluded location. It is possible 
that miR-338-5p facilitates GCSC division and conver-
sion into differentiated GC cells, which are more suscep-
tible to chemotherapy, thus changing quiescent GCSCs 
to a more vulnerable state. miR-338-5p may first induce 
GCSCs to divide and differentiate and then promote their 
apoptosis via unrelated mechanisms. In previous studies, 
GCSCs were found to be enriched in CD44+ MKN45 and 
MKN74 cells [5, 19], whereas ACBP-3 could decrease 
the ratio of CD44+/CD44− cells, which provides sup-
port for our hypothesized mechanism of miR-338-5p 
activity. Further experiments are required to test these 
speculations.
BAK and BIM are pro-apoptotic members of the 
BCL-2 family, which controls the mitochondrial apop-
totic pathway [37]. The results indicated that BAK and 
BIM levels correlated with miR-338-5p expression in 
GCSCs, suggesting that these proteins may be induced 
by ACBP-3 via miR-338-5p upregulation and then trigger 
the apoptosis of GCSCs. This mechanism can provide an 
explanation for the anticancer effects of ACBP-3 related 
to GCSC apoptosis [5].
DDP and 5-FU are representative platinum-based and 
fluorouracil-based chemotherapeutic drugs widely used 
as first-line anti-cancer agents in the clinic. However, 
they exert severe side effects, including myeloid suppres-
sion, hepatotoxicity, ototoxicity, gastrointestinal toxicity, 
nephrotoxicity, and peripheral neuropathy [38], which are 
exacerbated if different drugs are combined. Our previous 
results indicated that ACBP-3 could lower the effective 
dose of DDP [5] and improve the quality of life of tumor-
bearing mice [5, 39]. In this study, we observed that the 
combination of ACBP-3 with DDP and 5-FU at 0.5 IC50 
resulted in stronger inhibition of GCSC proliferation 
compared with the drugs alone; in addition, the potentiat-
ing effect correlated with miR-338-5p expression. As our 
results indicate, the anticancer efficiency of DDP or 5-FU, 
which is much stronger than that of ACBP-3, does not 
depend on miR-338-5p expression, suggesting other can-
cer-suppressive mechanisms, which may not be sufficient 
to overcome GCSC resistance. Therefore, the combina-
tion of these mechanisms and miR-338-5p upregulation 
exerted by ACBP-3 may be efficient against GCSCs.
ACBP-3 is a natural compound with low in vivo cyto-
toxicity [5]. Combined with strong anti-cancer chemo-
therapeutic agents, it may lower their effective dose by 
increasing miR-338-5p levels in GCSCs and increasing 
their sensitivity to chemotherapy while reducing the side 
effects of the drugs. In a previous study, we conducted a 
preliminary analysis of the composition of ACBP-3 [5]. In 
the future, we plan to identify each component and per-
form detailed functional evaluation, as well as provide 
further mechanistic insights into ACBP-3 activity.
Conclusions
Our results show, for the first time, that miR-338-5p 
plays an important role in the inhibition of human gastric 
cancer stem cell proliferation by ACBP-3 combined with 
chemotherapeutics. ACBP-3 upregulated miR-338-5p 
expression, increased BAK and BIM levels, promoted 
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apoptosis and inhibited the proliferation of GCSCs. Our 
results suggest that ACBP-3 could lower the effective 




ACBP-3 was isolated from goat liver as previously 
described [40].
Isolation of GCSCs from human GC cells
GC MKN45 cells were purchased from the Cell Resource 
Center, Institute of Basic Medical Sciences, Chinese 
Academy of Medical Sciences, Peking Union Medical Col-
lege (Beijing, China). MKN74 and GES-1 cells were a gift 
from the laboratory of Prof. Yang K (Health Center at the 
Peking University College of Medicine, Beijing, China). 
The cells were cultured in RPMI-1640 (Gibco BRL, Gaith-
ersburg, MD, USA) with 1 % penicillin–streptomycin and 
10  % fetal bovine serum (FBS; JRH Biosciences, Lenexa, 
KS, USA) at 37  °C in a humidified 5  % CO2 incubator. 
Spheroid colony-derived cells, which constitute a very 
small proportion of MKN45 and MKN74 GC cells, were 
identified as GCSCs according to a published method 
[5]. GCSCs from MKN45 cells were treated with 22  μg/
ml ACBP-3 or the same volume of PBS (control). The 
authenticity of these cell lines was confirmed by the Cell 
Resource Center, Institute of Basic Medical Sciences, 
Chinese Academy of Medical Sciences, Peking Union 
Medical College. No authentication of these cell lines was 
performed by the authors.
Total RNA extraction
Total RNA was extracted from the treated GCSCs and 
tumor tissues using Trizol (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions. RNA con-
centration was determined using a NanoDrop 2000 spec-
trophotometer (Thermo Scientific, Wilmington, DE, 
USA), and its integrity was confirmed by denaturing gel 
electrophoresis.
Microarray experiments
miRNA expression profiling was performed using Affy-
metrix GeneChip miRNA 3.0 arrays (Affymetrix, Santa 
Clara, CA, USA) containing 19,931 human mature 
miRNAs in miRBase 17 (http://www.mirbase.org). 
miRNA expression data are available from the NCBI 
Gene expression omnibus (GEO). Data processing 
including gene ontology (GO) analysis [41], pathway 
analysis [42, 43], miRNA-gene-network analysis [44–
46] and miRNA-GO-network analysis was performed 
using the Affymetrix Expression Console software (ver-
sion 1.2).
Quantitative real‑time PCR
Selected miRNAs were validated by qRT-PCR. Specific 
miRNA primers were provided by TIANGEN Biotech 
(Beijing) Co., Ltd. (Beijing, China), and qRT-PCR was 
performed using SYBR-Green PCR Master Mix (Takara) 
and a MX3000P qRT-PCR system (Strata gene) accord-
ing to the manufacturer’s recommendations. U6 small 
nuclear RNA was used as a reference gene for normaliza-
tion. Relative miRNA expression was calculated using the 
ΔCT method [47].
Overexpression and inhibition of the target miRNA 
in GCSCs
GCSCs isolated from MKN45 and MKN74 cells were 
seeded in 96-well plates at 3  ×  105 cells/well in antibi-
otic-free Opti-MEM supplemented with 10  % FBS and 
transiently transfected with miR-338-5p mimic or its 
inhibitor (RIBOBIO, Guangzhou, China) using Lipo-
fectamine 2000 (Thermo Fisher Scientific, Waltham, 
MA, USA) according to the manufacturer’s instructions; 
vector-transfected cells served as a control. After 24 h of 
incubation at 37  °C in a humidified 5  % CO2 incubator, 
the cells were changed into fresh complete medium and 
cultured for different times.
GCSC proliferation, apoptosis, and cell cycle analysis
After GCSCs were transfected for 24, 48, and 72  h, 
1-(4, 5-dimethylthiazol-2-yl)-3, 5-diphenylformazan 
thiazolyl blue formazan (MTT formazan; Sigma, St. 
Louis, MO, USA) was added to the wells and incubated 
at 37 °C for 5 h. Then, 150 μl DMSO was added to each 
well; the 96-well plates were rotated for 10 min to dis-
solve the purple crystals, and the absorbance at 490 nm 
was measured using an ELISA plate reader (Biotek 
Instruments, Highland Park, VT, USA). Apoptosis and 
the cell cycle were analyzed in GCSCs transfected for 
48  h using the Annexin V Apoptosis Detection Kit 
(eBioscience, San Diego, CA, USA) and ribonuclease 
(Worthington Biochemical Corp, Lakewood, NJ, USA) 
according to the manufacturer’s instructions using a 
flow cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA).
Western blot detection of apoptotic proteins
GCSCs transfected with miRNAs or treated with 
drugs were harvested, lysed with lysis buffer (1  % 
Triton X-100, 1  mM EGTA, 0.5  % NP-40, 10  mM 
HEPES (pH 7.4), 1  mM EDTA, 0.15  M NaCl) supple-
mented with protease inhibitor cocktail (Cell Signal-
ing Technology, Beverly, MA, USA), and sonicated 
on ice for 10  s. After incubation on ice for 30  min, 
the lysate was centrifuged at 13,000 rpm for 15 min at 
4  °C, the supernatant was collected, and the protein 
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concentration was determined using the Bicinchoninic 
Acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, 
USA). Then, 50 g of each lysate was boiled in 5× load-
ing buffer (50 % glycerol, 1 M Tris–HCl, pH 6.8, 10 % 
β-mercaptoethanol, 10 % SDS, 1 % bromophenol blue), 
cooled on ice, and separated by SDS-PAGE in 12  % 
gels. The resolved proteins were analyzed by west-
ern blotting using anti-BIM and anti-BAK antibodies 
(Abcam, Cambridge, MA, USA) and their correspond-
ing secondary antibodies.
Dose determination for chemotherapeutic drugs
GCSCs were seeded in complete medium in 96-well 
plates in sextuplicate for 24 h and then treated with 2.5–
60 μg/ml 5-FU (Jinyao Pharmaceutical Co., Ltd, Tianjin, 
China) or 1–21 μg/ml DDP (Haosen Pharmaceutical Co., 
Ltd., Jiangsu, China). Cultures treated with normal saline 
served as a control. The cell viability was determined after 
24, 48, 72 h by the MTT method, and the absorbance at 
490 nm was measured using an ELISA plate reader. The 
inhibition rate (IR) was calculated as (1−A/B) × 100 %, 
where A and B are the absorbance values of drug-treated 
and control cells, respectively, and was used to determine 
the IC50 for each drug.
Statistical analysis
We used the random-variance model (RVM) t test to 
compare two experimental groups and the RVM F test to 
compare more than two groups. The RVM model is used 
to analyze microarray data and screen for differentially 
expressed genes because it effectively raises the degrees 
of freedom for small samples. After the significance and 
false discovery rate (FDR) analyses, we selected differen-
tially expressed genes according to a P value considered 
significant at less than 0.05 [48–50].
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